Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency

NCT00365157 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00365157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00365157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 23, 2006
Completion date
July 9, 2027
Enrollment
171 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial carcinoma, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, recurrent urothelial carcinoma, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iv bladder urothelial carcinoma ajcc v7, unresectable urothelial carcinoma